Therapy of Adult Respiratory Distress Syndrome with Alpha-1- Antiproteinase or Lung Surfactant.
Abstract
Two clinical pilot studies were accomplished. The first focused on the administration of alpha-1 proteinase inhibitor to patients with the adult respiratory distress syndrome and had the goals of determining safety, describing pharmacokinetic parameters, and determining whether intravenous administration would augment functional antiprotease activity of blood and/or bronchoalveolar lavage fluid. Results indicate; (1) administration of alpha-1 PI was safety; (2) both initial and steady state clearance of alpha-1 from the central volume of distribution were enhanced; (3) infused alpha-1 retained all of its functional activity; (4) lung lavage levels of alpha-1 did not increase after intravenous infusion of alpha-1 PI; and (5) the calculated of the infused alpha-1 PI to those levels was significant. The second pilot study focused on the possible benefits to gas exchange and lung compliance that might accompany administration of exogenous lung surfactant to patients within the first 48 hours of development of ARDS.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 15, 1991
- Accession Number
- ADA239010
Entities
People
- Roger G. Spragg
Organizations
- University of California, San Diego